Cost-effectiveness of pneumococcal conjugate vaccination in Georgia
Highlights • Georgia is graduating from Gavi support at the end of 2015. • Georgia evaluated the cost-effectiveness of the introduction of PCV 10. • Introduction of PCV 10 is highly cost-effective from the Georgian government perspective.
Gespeichert in:
| Veröffentlicht in: | Vaccine 2015-05, Vol.33, p.A219-A226 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | A226 |
|---|---|
| container_issue | |
| container_start_page | A219 |
| container_title | Vaccine |
| container_volume | 33 |
| creator | Komakhidze, T Hoestlandt, C Dolakidze, T Shakhnazarova, M Chlikadze, R Kopaleishvili, N Goginashvili, K Kherkheulidze, M Clark, A.D Blau, J |
| description | Highlights • Georgia is graduating from Gavi support at the end of 2015. • Georgia evaluated the cost-effectiveness of the introduction of PCV 10. • Introduction of PCV 10 is highly cost-effective from the Georgian government perspective. |
| doi_str_mv | 10.1016/j.vaccine.2014.12.070 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1717495077</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X14017253</els_id><sourcerecordid>1677894740</sourcerecordid><originalsourceid>FETCH-LOGICAL-c528t-b68a577de9d6ab1b5f80fb5645861aac62b705e4ee2852d727d4557dbbe64f8e3</originalsourceid><addsrcrecordid>eNqFkk1v1DAQhi0EotvCTwBF4sIlqcfxVy4gtIJSqVIPBYmb5TiTyiFrL3GyUv89jnYLUi89-fK872j8DCHvgFZAQV4O1cE65wNWjAKvgFVU0RdkA1rVJROgX5INZZKXHOivM3Ke0kApFTU0r8kZEw00IMWGbLcxzSX2PbrZHzBgSkXsi33AZRdddM6OhYthWO7tjMVxpJ19DIUPxRXG6d7bN-RVb8eEb0_vBfn57euP7ffy5vbqevvlpnSC6blspbZCqQ6bTtoWWtFr2rdCcqElWOskaxUVyBGZFqxTTHVcCNW1LUrea6wvyMdj736KfxZMs9n55HAcbcC4JAMKFG8EVep5VCqlG644zeiHJ-gQlynkRVaK506heabEkXJTTGnC3uwnv7PTgwFqViFmMCchZhVigJksJOfen9qXdofdv9SjgQx8PgKYf-7gcTLJeQwOOz9lJ6aL_tkRn540uNEHn839xgdM_7cxKQfM3XoV61EAp6CYqOu_OBmyvQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1674717584</pqid></control><display><type>article</type><title>Cost-effectiveness of pneumococcal conjugate vaccination in Georgia</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Komakhidze, T ; Hoestlandt, C ; Dolakidze, T ; Shakhnazarova, M ; Chlikadze, R ; Kopaleishvili, N ; Goginashvili, K ; Kherkheulidze, M ; Clark, A.D ; Blau, J</creator><creatorcontrib>Komakhidze, T ; Hoestlandt, C ; Dolakidze, T ; Shakhnazarova, M ; Chlikadze, R ; Kopaleishvili, N ; Goginashvili, K ; Kherkheulidze, M ; Clark, A.D ; Blau, J</creatorcontrib><description>Highlights • Georgia is graduating from Gavi support at the end of 2015. • Georgia evaluated the cost-effectiveness of the introduction of PCV 10. • Introduction of PCV 10 is highly cost-effective from the Georgian government perspective.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2014.12.070</identifier><identifier>PMID: 25919165</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Allergy and Immunology ; Child, Preschool ; Cost-Benefit Analysis ; Cost-effectiveness analysis ; Decision-making process ; Economics ; Evidence-based medicine ; Georgia ; Georgia (Republic) - epidemiology ; Health Policy ; Humans ; Immunization ; Immunization Programs ; Infant ; Infant, Newborn ; Meningitis ; Models, Statistical ; Mortality ; Pneumococcal conjugate vaccine ; Pneumococcal Infections - economics ; Pneumococcal Infections - epidemiology ; Pneumococcal Infections - prevention & control ; Pneumococcal Vaccines - administration & dosage ; Pneumococcal Vaccines - economics ; Pneumococcal Vaccines - immunology ; Pneumonia ; Streptococcus pneumoniae ; Vaccination - economics ; Vaccination - methods ; Vaccines</subject><ispartof>Vaccine, 2015-05, Vol.33, p.A219-A226</ispartof><rights>Elsevier Ltd</rights><rights>2015 Elsevier Ltd</rights><rights>Copyright © 2015 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited May 7, 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c528t-b68a577de9d6ab1b5f80fb5645861aac62b705e4ee2852d727d4557dbbe64f8e3</citedby><cites>FETCH-LOGICAL-c528t-b68a577de9d6ab1b5f80fb5645861aac62b705e4ee2852d727d4557dbbe64f8e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1674717584?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25919165$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Komakhidze, T</creatorcontrib><creatorcontrib>Hoestlandt, C</creatorcontrib><creatorcontrib>Dolakidze, T</creatorcontrib><creatorcontrib>Shakhnazarova, M</creatorcontrib><creatorcontrib>Chlikadze, R</creatorcontrib><creatorcontrib>Kopaleishvili, N</creatorcontrib><creatorcontrib>Goginashvili, K</creatorcontrib><creatorcontrib>Kherkheulidze, M</creatorcontrib><creatorcontrib>Clark, A.D</creatorcontrib><creatorcontrib>Blau, J</creatorcontrib><title>Cost-effectiveness of pneumococcal conjugate vaccination in Georgia</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Highlights • Georgia is graduating from Gavi support at the end of 2015. • Georgia evaluated the cost-effectiveness of the introduction of PCV 10. • Introduction of PCV 10 is highly cost-effective from the Georgian government perspective.</description><subject>Allergy and Immunology</subject><subject>Child, Preschool</subject><subject>Cost-Benefit Analysis</subject><subject>Cost-effectiveness analysis</subject><subject>Decision-making process</subject><subject>Economics</subject><subject>Evidence-based medicine</subject><subject>Georgia</subject><subject>Georgia (Republic) - epidemiology</subject><subject>Health Policy</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization Programs</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Meningitis</subject><subject>Models, Statistical</subject><subject>Mortality</subject><subject>Pneumococcal conjugate vaccine</subject><subject>Pneumococcal Infections - economics</subject><subject>Pneumococcal Infections - epidemiology</subject><subject>Pneumococcal Infections - prevention & control</subject><subject>Pneumococcal Vaccines - administration & dosage</subject><subject>Pneumococcal Vaccines - economics</subject><subject>Pneumococcal Vaccines - immunology</subject><subject>Pneumonia</subject><subject>Streptococcus pneumoniae</subject><subject>Vaccination - economics</subject><subject>Vaccination - methods</subject><subject>Vaccines</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkk1v1DAQhi0EotvCTwBF4sIlqcfxVy4gtIJSqVIPBYmb5TiTyiFrL3GyUv89jnYLUi89-fK872j8DCHvgFZAQV4O1cE65wNWjAKvgFVU0RdkA1rVJROgX5INZZKXHOivM3Ke0kApFTU0r8kZEw00IMWGbLcxzSX2PbrZHzBgSkXsi33AZRdddM6OhYthWO7tjMVxpJ19DIUPxRXG6d7bN-RVb8eEb0_vBfn57euP7ffy5vbqevvlpnSC6blspbZCqQ6bTtoWWtFr2rdCcqElWOskaxUVyBGZFqxTTHVcCNW1LUrea6wvyMdj736KfxZMs9n55HAcbcC4JAMKFG8EVep5VCqlG644zeiHJ-gQlynkRVaK506heabEkXJTTGnC3uwnv7PTgwFqViFmMCchZhVigJksJOfen9qXdofdv9SjgQx8PgKYf-7gcTLJeQwOOz9lJ6aL_tkRn540uNEHn839xgdM_7cxKQfM3XoV61EAp6CYqOu_OBmyvQ</recordid><startdate>20150507</startdate><enddate>20150507</enddate><creator>Komakhidze, T</creator><creator>Hoestlandt, C</creator><creator>Dolakidze, T</creator><creator>Shakhnazarova, M</creator><creator>Chlikadze, R</creator><creator>Kopaleishvili, N</creator><creator>Goginashvili, K</creator><creator>Kherkheulidze, M</creator><creator>Clark, A.D</creator><creator>Blau, J</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20150507</creationdate><title>Cost-effectiveness of pneumococcal conjugate vaccination in Georgia</title><author>Komakhidze, T ; Hoestlandt, C ; Dolakidze, T ; Shakhnazarova, M ; Chlikadze, R ; Kopaleishvili, N ; Goginashvili, K ; Kherkheulidze, M ; Clark, A.D ; Blau, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c528t-b68a577de9d6ab1b5f80fb5645861aac62b705e4ee2852d727d4557dbbe64f8e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Allergy and Immunology</topic><topic>Child, Preschool</topic><topic>Cost-Benefit Analysis</topic><topic>Cost-effectiveness analysis</topic><topic>Decision-making process</topic><topic>Economics</topic><topic>Evidence-based medicine</topic><topic>Georgia</topic><topic>Georgia (Republic) - epidemiology</topic><topic>Health Policy</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization Programs</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Meningitis</topic><topic>Models, Statistical</topic><topic>Mortality</topic><topic>Pneumococcal conjugate vaccine</topic><topic>Pneumococcal Infections - economics</topic><topic>Pneumococcal Infections - epidemiology</topic><topic>Pneumococcal Infections - prevention & control</topic><topic>Pneumococcal Vaccines - administration & dosage</topic><topic>Pneumococcal Vaccines - economics</topic><topic>Pneumococcal Vaccines - immunology</topic><topic>Pneumonia</topic><topic>Streptococcus pneumoniae</topic><topic>Vaccination - economics</topic><topic>Vaccination - methods</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Komakhidze, T</creatorcontrib><creatorcontrib>Hoestlandt, C</creatorcontrib><creatorcontrib>Dolakidze, T</creatorcontrib><creatorcontrib>Shakhnazarova, M</creatorcontrib><creatorcontrib>Chlikadze, R</creatorcontrib><creatorcontrib>Kopaleishvili, N</creatorcontrib><creatorcontrib>Goginashvili, K</creatorcontrib><creatorcontrib>Kherkheulidze, M</creatorcontrib><creatorcontrib>Clark, A.D</creatorcontrib><creatorcontrib>Blau, J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Komakhidze, T</au><au>Hoestlandt, C</au><au>Dolakidze, T</au><au>Shakhnazarova, M</au><au>Chlikadze, R</au><au>Kopaleishvili, N</au><au>Goginashvili, K</au><au>Kherkheulidze, M</au><au>Clark, A.D</au><au>Blau, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cost-effectiveness of pneumococcal conjugate vaccination in Georgia</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2015-05-07</date><risdate>2015</risdate><volume>33</volume><spage>A219</spage><epage>A226</epage><pages>A219-A226</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Highlights • Georgia is graduating from Gavi support at the end of 2015. • Georgia evaluated the cost-effectiveness of the introduction of PCV 10. • Introduction of PCV 10 is highly cost-effective from the Georgian government perspective.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>25919165</pmid><doi>10.1016/j.vaccine.2014.12.070</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2015-05, Vol.33, p.A219-A226 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1717495077 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Allergy and Immunology Child, Preschool Cost-Benefit Analysis Cost-effectiveness analysis Decision-making process Economics Evidence-based medicine Georgia Georgia (Republic) - epidemiology Health Policy Humans Immunization Immunization Programs Infant Infant, Newborn Meningitis Models, Statistical Mortality Pneumococcal conjugate vaccine Pneumococcal Infections - economics Pneumococcal Infections - epidemiology Pneumococcal Infections - prevention & control Pneumococcal Vaccines - administration & dosage Pneumococcal Vaccines - economics Pneumococcal Vaccines - immunology Pneumonia Streptococcus pneumoniae Vaccination - economics Vaccination - methods Vaccines |
| title | Cost-effectiveness of pneumococcal conjugate vaccination in Georgia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T02%3A28%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cost-effectiveness%20of%20pneumococcal%20conjugate%20vaccination%20in%20Georgia&rft.jtitle=Vaccine&rft.au=Komakhidze,%20T&rft.date=2015-05-07&rft.volume=33&rft.spage=A219&rft.epage=A226&rft.pages=A219-A226&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2014.12.070&rft_dat=%3Cproquest_cross%3E1677894740%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1674717584&rft_id=info:pmid/25919165&rft_els_id=S0264410X14017253&rfr_iscdi=true |